Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 4, 2009, Pages 509-513

  Elgqvist, Jörgen ^a   Andersson, Håkan ^a   Haglund, Elin ^a   Jensen, Holger ^b   Kahu, Helena ^a   Lindegren, Sture ^a   Warnhammar, Elisabet ^a   Hultborn, Ragnar ^a  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b Rigshospitalet   (Denmark)

Author keywords

211At; Alpha; Astatine; Intraperitoneal; Mice; Ovarian cancer; Radioimmunotherapy; Specific activity

Indexed keywords

ASTATINE 211; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MX35; MONOCLONAL ANTIBODY MX35 IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY MX35 IMMUNOGLOBULIN F(AB')2 FRAGMENT AT 211; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYCLOTRON; DRUG EFFICACY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; OVARY CANCER; PERITONEAL BIOPSY; PERITONEUM TUMOR; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; INFUSIONS, PARENTERAL; MICE; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 69249107784     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0618     Document Type: Article

References (29)

1. Zalutsky MR, Reardon DA, Pozzi OR, et al. Targeted α-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol 2007;34:779.
2. McQuarrie S, Mercer J, Syme A, et al. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Pharm Sci 2005;7:29.
3. Janssen ML, Pels W, Massuger LF, et al. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide. Int J Gynecol Cancer 2003;13:607.
4. Borchardt PE, Quadri SM, Freedman RS, et al. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis. Cancer Biother Radiopharm 2000;15:53.
5. Grana C, Bartolomei M, Handkiewicz D, et al. Radioimmunotherapy in advanced ovarian cancer: Is there a role for pretargeting with (90)Y-biotin? Gynecol Oncol 2004;93:691.
6. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm 2001;16:305.
7. Mahe MA, Fumoleau P, Fabbro M, et al. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 1999;5:3249.
8. Epenetos AA, Hird V, Lambert H, et al. Long-term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 2000;10:44.
9. 177Lu-CC49: A phase I=II study. Gyncol Oncol 1997;65:94.
10. 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2002;8:2806.
11. Stewart JSW, Hird V, Snook D, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990;8:1941.
12. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006;24:571.
13. Oei AL, Verheijen RH, Seiden MV, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 2007;120:2710.
14. Andersson H, Elgqvist J, Horvath G, et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: An overview of results in an ovarian tumor model. Clin Cancer Res 2003;9:3914.
15. 211At-labelled monoclonal antibody MOv18. Anticancer Res 2000;20:459.
16. 211At in nude mice with intraperitoneally growing ovarian cancer xenografts: A long-term study. Acta Oncol 2000;39:741.
17. 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian carcinoma. Anticancer Res 2001;21:409.
18. 211At-labeled monoclonal antibody MX35. J Nucl Med 2005;46:1907.
19. 2. Int J Radiat Oncol Biol Phys 2006;66:1228.
20. Elgqvist J, Andersson H, Bäck T, et al. Alpharadioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med 2006;47:1342.
21. 60Co irradiation in nude mice. J Nucl Med 2005;46:464.
22. Bäck T, Andersson H, Divgi CR, et al. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an alpha-emitter in vivo. J Nucl Med 2005;46:2061.
23. Lindegren S, Bäck T, Jensen HJ. Dry-distillation of astatine-211 from irradiated bismuth targets: A time-saving procedure with high recovery yields. Appl Radiat Isot 2001;55:157.
24. Yin BW, Kiamova R, Chua R, et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun 2008;8:3.
25. Rubin SC, Kostakoglu L, Divgi C, et al. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol Oncol 1993;51:61.
26. Lindegren S, Andersson H, Bäck T, et al. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidizing agent in labeling of N-succinimidyl 3-(trimethylstannyl)benzoate. Nucl Med Biol 2001;28:33.
27. Hamilton TC, Young RC, McKoy WM, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983;43:5379.
28. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Met 1984;72:77.
29. 2-a phase I study. J Nucl Med 2009;50:1153.